BioNTech SE (BNTX) Stock Analysis — Fair Value, Risk & Moat Rating
NMS · Healthcare · Biotechnology
Is BioNTech SE a safe investment right now?
Trading at $111.60, BioNTech SE (BNTX) in the Healthcare sector does not have sufficient data for a reliable fair value estimate. An Altman Z-Score of 8.01 confirms the company is in the safe zone — financial distress is unlikely near-term. Our moat rating stands at 2.3/5 stars (Weak moat), suggesting limited pricing power in a competitive landscape.
Could BioNTech SE go bankrupt? Altman Z-Score analysis
Z-Score of 8.01 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives BNTX's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.6369 | 1.2 | 0.76 |
| B · Retained Earnings / Total Assets | RE / TA | 0.8169 | 1.4 | 1.14 |
| C · EBIT / Total Assets | EBIT / TA | -0.0471 | 3.3 | -0.16 |
| D · Market Cap / Total Liabilities | MCap / TL | 10.209 | 0.6 | 6.13 |
| E · Revenue / Total Assets | Rev / TA | 0.1305 | 1.0 | 0.13 |
How has BNTX's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 9.95 | Safe |
| 2023 | 8.58 | Safe |
| 2024 | 7.51 | Safe |
| 2025 | 8.01 | Safe |
Source: Calculated from BNTX's latest 10-K filing on SEC EDGAR.
What is BioNTech SE actually worth?
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does BioNTech SE have a durable competitive advantage?
Moat rating: 2.3/5.
What makes up BNTX's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 2/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 2/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is BNTX's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 60.0% | — |
| 2023 | 5.8% | Declining |
| 2024 | -3.4% | Declining |
| 2025 | -5.3% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is BioNTech SE's dividend safe?
BioNTech SE's key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $2.9B | $2.8B | $17.3B | Declining |
| Net Income | −$1.1B | −$0.7B | $9.4B | Declining |
| Free Cash Flow | −$0.3B | −$0.2B | $13.2B | Declining |
| Gross Margin | 77.6% | 80.3% | 82.7% | Declining |
Common questions about BioNTech SE
Is BioNTech SE at risk of going bankrupt?
BioNTech SE's Altman Z-Score of 8.01 places it in the safe zone. This metric uses balance sheet ratios to predict bankruptcy probability within 2 years. A score below 1.8 signals distress, while above 3.0 indicates safety.
Why is there no fair value estimate for BioNTech SE?
A reliable fair value estimate requires stable, positive free cash flow or earnings data. This stock may lack sufficient data, or it may be classified as speculative where traditional valuation does not apply.
Does BioNTech SE have a competitive moat?
BioNTech SE receives a moat rating of 2.3 out of 5 stars, based on ROIC stability, gross margin trends, and estimated switching costs. A rating above 3.5 suggests a durable competitive advantage.
Does BioNTech SE pay a dividend?
BioNTech SE does not currently pay a regular dividend, or has suspended its dividend. Check the dividend safety section for the latest status.
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 20, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
BNTX analysis methodology: How we calculate fair value, Z-Scores, and moat ratings